Itır Ebru Zemheri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Itır Ebru Zemheri has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Ayse Serap Karadag
Department of Dermatology Memorial Atasehir Hospital Istanbul Turkey
5 shared publications - Tugba Kevser Uzuncakmak
Cerrahpasa Medical Faculty, Department of Dermatology and Venereology Istanbul University‐Cerrahpasa Istanbul Turkey
5 shared publications - Dilek Telci
Yeditepe University
4 shared publications - Necmettin Akdeniz
İstanbul Medeniyet Üniversitesi
4 shared publications - Asuman Bozkir
Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Ankara, Turkey
3 shared publications - Ayca Ece Nezir
Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University
3 shared publications
Latest Publications
- 23 April 2026
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (6) , 1468-1482
Mismatch Repair Deficiency and Programmed Death-Ligand 1 Expression in Treatment-Naïve High-Risk and Very High-Risk Locally Advanced Prostate Cancer: Histomorphological Associations and Prognostic Value
High-risk (HR) and very high-risk (VHR) prostate cancer (PCa) are associated with poor outcomes despite multimodal therapy. Although immunotherapy is a last-line option for advanced disease, its role in locally advanced prostate cancer (LAPCa) remains unclear. This study aimed to evaluate the association between programmed death-ligand 1 (PD-L1) expression, mismatch repair deficiency (dMMR), and histomorphological features, and to assess their prognostic significance in treatment-naïve HR/VHR LAPCa. Eighty-five patients who underwent robotic radical prostatectomy between 2014 and 2024 were retrospectively analyzed. Clinicopathological variables were assessed comprehensively. MMR status was determined using immunohistochemistry, and loss of expression prompted microsatellite instability analysis by polymerase chain reaction. PD-L1 expression was evaluated using tumor proportion score, immune cell proportion score, and combined positive score (CPS). Binary logistic regression was used to identify independent predictors of PD-L1 CPS positivity. Survival outcomes were analyzed using Kaplan-Meier and Cox regression analyses. The cohort comprised 41 HR and 44 VHR LAPCa patients, and dMMR was identified in 2 patients (2.4%), both in VHR group. Ductal adenocarcinoma component, higher tumor volume, and increased tumor-infiltrating lymphocyte score independently predicted PD-L1 CPS positivity. Among VHR patients, PD-L1 CPS positivity was associated with shorter biochemical recurrence-free survival (BCRFS). In the entire cohort, ductal adenocarcinoma component was an independent prognostic factor for BCRFS, whereas lymphovascular invasion independently predicted metastasis-free survival. dMMR and PD-L1 positivity are rare in HR/VHR LAPCa, supporting “cold” tumor profile. Routine testing may be unnecessary; however, selective histopathology-based biomarker assessment could improve risk stratification and inform personalized therapies.
- 23 April 2026
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (6) , 1468-1482
Mismatch Repair Deficiency and Programmed Death-Ligand 1 Expression in Treatment-Naïve High-Risk and Very High-Risk Locally Advanced Prostate Cancer: Histomorphological Associations and Prognostic Value
High-risk (HR) and very high-risk (VHR) prostate cancer (PCa) are associated with poor outcomes despite multimodal therapy. Although immunotherapy is a last-line option for advanced disease, its role in locally advanced prostate cancer (LAPCa) remains unclear. This study aimed to evaluate the association between programmed death-ligand 1 (PD-L1) expression, mismatch repair deficiency (dMMR), and histomorphological features, and to assess their prognostic significance in treatment-naïve HR/VHR LAPCa. Eighty-five patients who underwent robotic radical prostatectomy between 2014 and 2024 were retrospectively analyzed. Clinicopathological variables were assessed comprehensively. MMR status was determined using immunohistochemistry, and loss of expression prompted microsatellite instability analysis by polymerase chain reaction. PD-L1 expression was evaluated using tumor proportion score, immune cell proportion score, and combined positive score (CPS). Binary logistic regression was used to identify independent predictors of PD-L1 CPS positivity. Survival outcomes were analyzed using Kaplan-Meier and Cox regression analyses. The cohort comprised 41 HR and 44 VHR LAPCa patients, and dMMR was identified in 2 patients (2.4%), both in VHR group. Ductal adenocarcinoma component, higher tumor volume, and increased tumor-infiltrating lymphocyte score independently predicted PD-L1 CPS positivity. Among VHR patients, PD-L1 CPS positivity was associated with shorter biochemical recurrence-free survival (BCRFS). In the entire cohort, ductal adenocarcinoma component was an independent prognostic factor for BCRFS, whereas lymphovascular invasion independently predicted metastasis-free survival. dMMR and PD-L1 positivity are rare in HR/VHR LAPCa, supporting “cold” tumor profile. Routine testing may be unnecessary; however, selective histopathology-based biomarker assessment could improve risk stratification and inform personalized therapies.
- Open Access
- 11 February 2025
- Published by Wiley in Journal of Applied Polymer Science
- Vol. 142 (18)
Anticancer Activity of Soy Lecithin‐Based Curcumin in Prostate Cancer
Prostate cancer, the second leading cause of cancer‐related deaths, has driven research into drug delivery systems to overcome the limitations of conventional chemotherapy. Curcumin, a phenolic phytochemical from Curcuma longa , shows antioxidant, anti‐mutagenic, anti‐proliferative, anti‐inflammatory, and anticancer properties. However, its low solubility and bioavailability limit its use, leading to the development of encapsulated formulations to enhance its efficacy. Carrier‐based curcumin formulations have emerged as a promising perspective for cancer treatment. Here, we aimed to assess the in vitro anticancer activity of soy lecithin‐encapsulated curcumin ( SLC CUR) and the safety and efficacy of its intracellular uptake against prostate cancer. To this end, the intracellular uptake and cytotoxic activity of SLC CUR versus free curcumin ( F CUR) were analyzed in androgen‐sensitive 22Rv1 and LNCaP prostate cancer cells along with normal prostate epithelial cells PNT1A. Cellular uptake of SLC CUR was 15‐fold higher than F CUR, showing a greater dose‐dependent cytotoxic effect on 22Rv1 and LNCaP cells, while only a cytostatic effect was observed for PNT1A cells. In a nude mice 22Rv1 xenograft model, administration of SLC CUR resulted in a tenfold greater reduction in tumor size compared to F CUR, suggesting that the anticancer activity of curcumin is significantly improved when encapsulated in soy lecithin‐based carriers.
- 11 February 2025
- Published by Wiley in Journal of Applied Polymer Science
- Vol. 142 (18)
Open AccessAnticancer Activity of Soy Lecithin‐Based Curcumin in Prostate Cancer
Prostate cancer, the second leading cause of cancer‐related deaths, has driven research into drug delivery systems to overcome the limitations of conventional chemotherapy. Curcumin, a phenolic phytochemical from Curcuma longa , shows antioxidant, anti‐mutagenic, anti‐proliferative, anti‐inflammatory, and anticancer properties. However, its low solubility and bioavailability limit its use, leading to the development of encapsulated formulations to enhance its efficacy. Carrier‐based curcumin formulations have emerged as a promising perspective for cancer treatment. Here, we aimed to assess the in vitro anticancer activity of soy lecithin‐encapsulated curcumin ( SLC CUR) and the safety and efficacy of its intracellular uptake against prostate cancer. To this end, the intracellular uptake and cytotoxic activity of SLC CUR versus free curcumin ( F CUR) were analyzed in androgen‐sensitive 22Rv1 and LNCaP prostate cancer cells along with normal prostate epithelial cells PNT1A. Cellular uptake of SLC CUR was 15‐fold higher than F CUR, showing a greater dose‐dependent cytotoxic effect on 22Rv1 and LNCaP cells, while only a cytostatic effect was observed for PNT1A cells. In a nude mice 22Rv1 xenograft model, administration of SLC CUR resulted in a tenfold greater reduction in tumor size compared to F CUR, suggesting that the anticancer activity of curcumin is significantly improved when encapsulated in soy lecithin‐based carriers.
- Open Access
- 15 October 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 48 (5) , 299-307
Delivery of BikDD Proapoptotic Gene in Peptide-18 Targeted Poly(2-oxazoline)-DOPE Nanoliposomes for Breast Cancer Models
Breast cancer is the most common cancer type and the major cause of death in females worldwide. For effective breast cancer treatment, systems with promising delivery of anticancer agents is an important strategy. Peptide 18 (P18), a tumor homing peptide, shows high binding affinity towards breast cancer cells. Nanoliposomes are known to have enhanced accumulation ability in tumors with longer systemic circulation. Poly (2-ethyl-2-oxazoline) (PEtOx) polymers conjugated with DOPE were used to prepare PEtOx-DOPE nanoliposomes. BikDD is a mutant form of Bik gene, a member of the BH3-only proapoptotic genes, mimics the constitutively phosphorylated form of the gene. To the best of our knowledge, this study presents a novel approach by investigating P18-conjugated PEtOX-DOPE nanoliposomes (P18-PEtOx-DOPE) for the targeted delivery of the BikDD gene to the AU565 breast cancer model. Site-directed mutated BikDD gene was loaded into P18-PEtOx-DOPE nanoliposome and then the targeted drug delivery system was assessed in vitro and in vivo breast cancer models for efficiency, safety and efficacy. The increased Bik mRNA expression levels in AU565 cells suggest high effectiveness of the targeting PEtOx-DOPE nanoliposomes. Following in vitro studies, the delivery of BikDD gene by P18-PEtOx-DOPE nanoliposomes were analyzed in CD-1 nude mice models. The animal study showed no significant difference in tumor volume of CD-1 nude mice treated with P18-PEtOx-DOPE-BikDD nanoliposomes when compared to the free delivery of BikDD gene. Our preclinical studies suggest that P18-PEtOx-DOPE-BikDD nanoliposomes may be promising gene carriers used in targeted breast cancer therapy. Thus, further studies should be carried out to determine the prolonged usage of this drug delivery system in breast cancer therapy.
- 15 October 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 48 (5) , 299-307
Open AccessDelivery of BikDD Proapoptotic Gene in Peptide-18 Targeted Poly(2-oxazoline)-DOPE Nanoliposomes for Breast Cancer Models
Breast cancer is the most common cancer type and the major cause of death in females worldwide. For effective breast cancer treatment, systems with promising delivery of anticancer agents is an important strategy. Peptide 18 (P18), a tumor homing peptide, shows high binding affinity towards breast cancer cells. Nanoliposomes are known to have enhanced accumulation ability in tumors with longer systemic circulation. Poly (2-ethyl-2-oxazoline) (PEtOx) polymers conjugated with DOPE were used to prepare PEtOx-DOPE nanoliposomes. BikDD is a mutant form of Bik gene, a member of the BH3-only proapoptotic genes, mimics the constitutively phosphorylated form of the gene. To the best of our knowledge, this study presents a novel approach by investigating P18-conjugated PEtOX-DOPE nanoliposomes (P18-PEtOx-DOPE) for the targeted delivery of the BikDD gene to the AU565 breast cancer model. Site-directed mutated BikDD gene was loaded into P18-PEtOx-DOPE nanoliposome and then the targeted drug delivery system was assessed in vitro and in vivo breast cancer models for efficiency, safety and efficacy. The increased Bik mRNA expression levels in AU565 cells suggest high effectiveness of the targeting PEtOx-DOPE nanoliposomes. Following in vitro studies, the delivery of BikDD gene by P18-PEtOx-DOPE nanoliposomes were analyzed in CD-1 nude mice models. The animal study showed no significant difference in tumor volume of CD-1 nude mice treated with P18-PEtOx-DOPE-BikDD nanoliposomes when compared to the free delivery of BikDD gene. Our preclinical studies suggest that P18-PEtOx-DOPE-BikDD nanoliposomes may be promising gene carriers used in targeted breast cancer therapy. Thus, further studies should be carried out to determine the prolonged usage of this drug delivery system in breast cancer therapy.
- Open Access
- 8 October 2024
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 41 (4) , 236-245
Evaluation of CD56 and CD117 Double-positive as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis
Objective: Despite advancements in treatment, multiple myeloma (MM) remains a challenging hematologic malignancy. It is crucial to stratify risk and perform prognostic assessment with various markers, including the expression of cluster of differentiation 56 (CD56) and cluster of differentiation 117 (CD117). However, the relationship of these markers with MM-related survival remains unclear. In this context, the objective of this study was to investigate the prognostic implications of CD56 and CD117 expression and associated clinical features in MM patients. Materials and Methods: The population of this retrospective single-center study consisted of adult MM patients whose CD56 and CD117 expression levels were analyzed. Patients were divided into four groups according to their immunophenotypes: CD56(+)CD117(-), CD56(-)CD117(+), CD56(+)CD117(+), and CD56(-)CD117(-). These groups were compared in terms of demographic and clinical characteristics, response to treatment, and survival outcomes. Results: Of the 168 MM patients included in the study, CD56 positivity, CD117 positivity, CD56 and CD117 double positivity, and CD56 and CD117 double negativity were observed in 57.1%, 38.1%, 21.4%, and 26.2%, respectively. Patients with double positivity had significantly higher cytogenetic risk and significantly lower overall response rate (ORR) compared to other patients (p<0.001 for both). ORR and overall survival (OS) were significantly lower in CD56(-)positive patients than in CD56(-)negative patients (p=0.017 and p=0.004, respectively). Mortality rates were significantly higher in CD56(-)positive and CD117positive patients than in double-negative patients (p<0.001 and p=0.002, respectively). Double-negative patients had significantly lower ORR and OS and higher mortality than others (p=0.001, p=0.002, and p0.001). Conclusion: This study's findings revealed that MM patients with CD56 and CD117 double positivity had poorer prognosis, lower ORR, shorter OS, and higher mortality.
- 8 October 2024
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 41 (4) , 236-245
Open AccessEvaluation of CD56 and CD117 Double-positive as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis
Objective: Despite advancements in treatment, multiple myeloma (MM) remains a challenging hematologic malignancy. It is crucial to stratify risk and perform prognostic assessment with various markers, including the expression of cluster of differentiation 56 (CD56) and cluster of differentiation 117 (CD117). However, the relationship of these markers with MM-related survival remains unclear. In this context, the objective of this study was to investigate the prognostic implications of CD56 and CD117 expression and associated clinical features in MM patients. Materials and Methods: The population of this retrospective single-center study consisted of adult MM patients whose CD56 and CD117 expression levels were analyzed. Patients were divided into four groups according to their immunophenotypes: CD56(+)CD117(-), CD56(-)CD117(+), CD56(+)CD117(+), and CD56(-)CD117(-). These groups were compared in terms of demographic and clinical characteristics, response to treatment, and survival outcomes. Results: Of the 168 MM patients included in the study, CD56 positivity, CD117 positivity, CD56 and CD117 double positivity, and CD56 and CD117 double negativity were observed in 57.1%, 38.1%, 21.4%, and 26.2%, respectively. Patients with double positivity had significantly higher cytogenetic risk and significantly lower overall response rate (ORR) compared to other patients (p<0.001 for both). ORR and overall survival (OS) were significantly lower in CD56(-)positive patients than in CD56(-)negative patients (p=0.017 and p=0.004, respectively). Mortality rates were significantly higher in CD56(-)positive and CD117positive patients than in double-negative patients (p<0.001 and p=0.002, respectively). Double-negative patients had significantly lower ORR and OS and higher mortality than others (p=0.001, p=0.002, and p0.001). Conclusion: This study's findings revealed that MM patients with CD56 and CD117 double positivity had poorer prognosis, lower ORR, shorter OS, and higher mortality.
- Open Access
- 26 June 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 48 (3) , 174-181
PEtOx-DOPE nanoliposomes functionalized with peptide 563 in targeted BikDDA delivery to prostate cancer
BackgroundNanocarrier-based systems have cultivated significant improvements in prostate cancer therapy. However, the efforts are still limited in clinical applicability, and more research is required for the development of effective strategies. Here, we describe a novel nanoliposomal system for targeted apoptotic gene delivery to prostate cancer.MethodsPoly (2-ethyl-2-oxazoline) (PEtOx) dioleoyl phosphatidylethanolamine (DOPE) nanoliposomes were conjugated with the prostate-specific membrane antigen (PSMA)-targeting peptide GRFLTGGTGRLLRIS (P563) and loaded with BikDDA, a mutant form of the proapoptotik Bik. We selected 22Rv1 cells with moderate upregulation of PSMA to test the in vitro uptake, cell death, and in vivo anti-cancer activity of our formulation, P563-PEtOx-DOPE-BikDDA.ResultsBikDDA was upregulated in 22Rv1 cells, inducing cell death, and CD-1 nude mice xenografts administered with the formulation showed significant tumor regression.ConclusionWe suggest that P563-PEtOx-DOPE-BikDDA nanoliposomes can serve as prominent gene carriers against prostate cancer.
- 26 June 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 48 (3) , 174-181
Open AccessPEtOx-DOPE nanoliposomes functionalized with peptide 563 in targeted BikDDA delivery to prostate cancer
BackgroundNanocarrier-based systems have cultivated significant improvements in prostate cancer therapy. However, the efforts are still limited in clinical applicability, and more research is required for the development of effective strategies. Here, we describe a novel nanoliposomal system for targeted apoptotic gene delivery to prostate cancer.MethodsPoly (2-ethyl-2-oxazoline) (PEtOx) dioleoyl phosphatidylethanolamine (DOPE) nanoliposomes were conjugated with the prostate-specific membrane antigen (PSMA)-targeting peptide GRFLTGGTGRLLRIS (P563) and loaded with BikDDA, a mutant form of the proapoptotik Bik. We selected 22Rv1 cells with moderate upregulation of PSMA to test the in vitro uptake, cell death, and in vivo anti-cancer activity of our formulation, P563-PEtOx-DOPE-BikDDA.ResultsBikDDA was upregulated in 22Rv1 cells, inducing cell death, and CD-1 nude mice xenografts administered with the formulation showed significant tumor regression.ConclusionWe suggest that P563-PEtOx-DOPE-BikDDA nanoliposomes can serve as prominent gene carriers against prostate cancer.
- 15 June 2023
- Published by Springer Nature in Amino Acids
- Vol. 55 (8) , 1023-1037
Targeting prostate cancer with docetaxel-loaded peptide 563-conjugated PEtOx-co-PEI30%-b-PCL polymeric micelle nanocarriers
Prostate cancer is a global disease that negatively affects the quality of life. Although various strategies against prostate cancer have been developed, only a few achieved tumor-specific targeting. Therefore, a special emphasis has been placed on the treatment of cancer using nano-carrier-encapsulated chemotherapeutic agents conjugated with tumor-homing peptides. The targeting strategy coupling the drugs with nanotechnology helps to overcome the most common barriers, such as high toxicity and side effects. Prostate-specific membrane antigen has emerged as a promising target molecule for prostate cancer and shown to be targeted with high affinity by GRFLTGGTGRLLRIS peptide known as peptide 563 (P563). Here, we aimed to assess the in vitro and in vivo targeting efficiency, safety, and efficacy of P563-conjugated, docetaxel (DTX)-loaded polymeric micelle nanoparticles (P563-PEtOx-co-PEI30%-b-PCL-DTX) against prostate cancer. To this end, we analyzed the cytotoxic activity of P563-PEtOx-co-PEI30%-b-PCL and P563-PEtOx-co-PEI30%-b-PCL-DTX by a cell proliferation assay using PNT1A and 22Rv1 cells. We have also determined the targeting selectivity of P563-PEtOx-co-PEI30%-b-PCL-FITC by flow cytometry and assessed the induction of cell death by western blot and TUNEL assays for P563-PEtOx-co-PEI30%-b-PCL-DTX in 22Rv1 cells. To investigate the in vivo efficacy, we administered DTX in the free form or in polymeric micelle nanoparticles to athymic CD-1 nu/nu mice 22Rv1 xenograft models and performed histopathological analyses. Our study showed that targeting prostate cancer with P563-conjugated PEtOx-co-PEI30%-b-PCL polymeric micelles could exert a potent anti-cancer activity with low side effects.
- 15 June 2023
- Published by Springer Nature in Amino Acids
- Vol. 55 (8) , 1023-1037
Targeting prostate cancer with docetaxel-loaded peptide 563-conjugated PEtOx-co-PEI30%-b-PCL polymeric micelle nanocarriers
Prostate cancer is a global disease that negatively affects the quality of life. Although various strategies against prostate cancer have been developed, only a few achieved tumor-specific targeting. Therefore, a special emphasis has been placed on the treatment of cancer using nano-carrier-encapsulated chemotherapeutic agents conjugated with tumor-homing peptides. The targeting strategy coupling the drugs with nanotechnology helps to overcome the most common barriers, such as high toxicity and side effects. Prostate-specific membrane antigen has emerged as a promising target molecule for prostate cancer and shown to be targeted with high affinity by GRFLTGGTGRLLRIS peptide known as peptide 563 (P563). Here, we aimed to assess the in vitro and in vivo targeting efficiency, safety, and efficacy of P563-conjugated, docetaxel (DTX)-loaded polymeric micelle nanoparticles (P563-PEtOx-co-PEI30%-b-PCL-DTX) against prostate cancer. To this end, we analyzed the cytotoxic activity of P563-PEtOx-co-PEI30%-b-PCL and P563-PEtOx-co-PEI30%-b-PCL-DTX by a cell proliferation assay using PNT1A and 22Rv1 cells. We have also determined the targeting selectivity of P563-PEtOx-co-PEI30%-b-PCL-FITC by flow cytometry and assessed the induction of cell death by western blot and TUNEL assays for P563-PEtOx-co-PEI30%-b-PCL-DTX in 22Rv1 cells. To investigate the in vivo efficacy, we administered DTX in the free form or in polymeric micelle nanoparticles to athymic CD-1 nu/nu mice 22Rv1 xenograft models and performed histopathological analyses. Our study showed that targeting prostate cancer with P563-conjugated PEtOx-co-PEI30%-b-PCL polymeric micelles could exert a potent anti-cancer activity with low side effects.
- Open Access
- 13 January 2023
- Published by Academician Publishing
Orofasial, Baş ve Boyun Ağrılarına Multidisipliner Yaklaşım
Bu eserimizde; ağız, baş ve boyun bölgesindeki ağrılardan yola çıkılarak multidisipliner yaklaşım ile bu bölge patolojileri ve güncel tanı ile tedavi yöntemleri ele alınmaktadır. Ağrı algısı, doku hasarına neden olan bir olayın bilinçli farkındalığıdır ve beynin korteksinde meydana gelen tatsız bir deneyim olarak tanımlanmaktadır. Ağız, baş ve boyun bölgesindeki ağrı yönetimi çok farklı branşları kapsamakla birlikte çeşitlilik göstermektedir. Boyun bölgesinde oluşan patolojiler, hem çocuklarda hem de yetişkinlerde zaman zaman görülebilen, basit bir enfeksiyonunun sonucu olabileceği gibi, bazen de ciddi hastalıkların bulgusu olabilmektedir.
- 13 January 2023
- Published by Academician Publishing
Open AccessOrofasial, Baş ve Boyun Ağrılarına Multidisipliner Yaklaşım
Bu eserimizde; ağız, baş ve boyun bölgesindeki ağrılardan yola çıkılarak multidisipliner yaklaşım ile bu bölge patolojileri ve güncel tanı ile tedavi yöntemleri ele alınmaktadır. Ağrı algısı, doku hasarına neden olan bir olayın bilinçli farkındalığıdır ve beynin korteksinde meydana gelen tatsız bir deneyim olarak tanımlanmaktadır. Ağız, baş ve boyun bölgesindeki ağrı yönetimi çok farklı branşları kapsamakla birlikte çeşitlilik göstermektedir. Boyun bölgesinde oluşan patolojiler, hem çocuklarda hem de yetişkinlerde zaman zaman görülebilen, basit bir enfeksiyonunun sonucu olabileceği gibi, bazen de ciddi hastalıkların bulgusu olabilmektedir.
- 23 April 2022
- Published by Academician Publishing
Patolojide Güncel Gelişmeler
Değerli meslektaşlarım, ortak kaderimiz, tıp biliminin belki de en hassas, en naif, en ilgiye muhtaç ve en yaşayan bilimini icra ediyor olmak. Tıp bilimine ait hemen tüm yenilikler ve gelişmeler patoloji bariyerini aşarak, patologlar tarafından kabul görüp, benimsenerek rutin pratikte yer bulabiliyor kendine. Bu nedenledir ki moleküler ayağımızın da bu denli canlı ve revaşta olduğu bir çağda bilgi birikimimizi canlı ve aktif tutmak kaçınılmaz. Bu kaygılarla özellikle genç meslektaşlarımın desteğini alarak güncel literatürler eşliğinde hemen her seksiyona ait belli konularda en güncel gelişmeleri sizlerle paylaşmak istedim. Hemen tüm nöronlarınızı birden aktif tutarak oluşturduğunuz kompleks sinapslarla hazırladığınız raporlarınızı güncel tutmak adına bir nebze katkı sağlayabilmek dileğiyle…
- 23 April 2022
- Published by Academician Publishing
Patolojide Güncel Gelişmeler
Değerli meslektaşlarım, ortak kaderimiz, tıp biliminin belki de en hassas, en naif, en ilgiye muhtaç ve en yaşayan bilimini icra ediyor olmak. Tıp bilimine ait hemen tüm yenilikler ve gelişmeler patoloji bariyerini aşarak, patologlar tarafından kabul görüp, benimsenerek rutin pratikte yer bulabiliyor kendine. Bu nedenledir ki moleküler ayağımızın da bu denli canlı ve revaşta olduğu bir çağda bilgi birikimimizi canlı ve aktif tutmak kaçınılmaz. Bu kaygılarla özellikle genç meslektaşlarımın desteğini alarak güncel literatürler eşliğinde hemen her seksiyona ait belli konularda en güncel gelişmeleri sizlerle paylaşmak istedim. Hemen tüm nöronlarınızı birden aktif tutarak oluşturduğunuz kompleks sinapslarla hazırladığınız raporlarınızı güncel tutmak adına bir nebze katkı sağlayabilmek dileğiyle…
- Open Access
- 1 January 2022
- Published by Türkiye Çocuk Cerrahisi Dernegi in Turkish Journal of Pediatric Surgery
- Vol. 36, No 2 (36, No 2) , 22-25
Çocuklarda Mezenter Kistlerinin Cerrahi Tedavi Sonuçları: Tek merkez deneyimi
Turkish Journal of Pediatric Surgery is a double-blind peer-reviewed, and international open-access journal. The journal has been published regularly since 1986.
- 1 January 2022
- Published by Türkiye Çocuk Cerrahisi Dernegi in Turkish Journal of Pediatric Surgery
- Vol. 36, No 2 (36, No 2) , 22-25
Open AccessÇocuklarda Mezenter Kistlerinin Cerrahi Tedavi Sonuçları: Tek merkez deneyimi
Turkish Journal of Pediatric Surgery is a double-blind peer-reviewed, and international open-access journal. The journal has been published regularly since 1986.
- Open Access
- 5 September 2021
- Published by Online Turk Saglik Bilimleri Dergisi in Online Türk Sağlık Bilimleri Dergisi
- Vol. 6 (3) , 426-432
Sildenafil ve Bacillus Clausii’nin Metotreksat Bağlı Mukozitin Önlenmesindeki Rolü: Preklinik Çalışma
Objective: Methotrexate (MTX) is a commonly used chemotherapeutic agent in clinical oncology practice and in treatment of autoimmune diseases. The major side effect during treatment is mucositis. Recently published studies reported that this effect may be due to direct intestinal epithelial injury and disturbance of intestinal microbiota. In this study, we aimed to characterize the intestinal histological changes caused by MTX and to investigate the effects and safety of Sildenafil and probiotic Bacillus clausii on intestinal mucositis in a rat model. Materials and Methods: The rats were divided in 4 groups; Group1(n=8) received MTX + B. clausii, Group 2 (n=8) received only MTX, Group3 (n=8) received MTX + Sildenafil and Group 4 (n=7) was served as control (received no treatment). Results: The rate of villus atrophy, villous fusion and erosion in the MTX + B. clausii group were found to be statistically significantly lower than in the MTX group and the MTX + Sildenafil group. Conclusion: The study demonstrated the effect of B. clausii on repairing of intestinal mucosa after MTX-treatment. The better understanding of the effects of probiotics on intestinal mucosal protection may lead to new therapeutic approaches in chemotherapy-induced mucositis.
- 5 September 2021
- Published by Online Turk Saglik Bilimleri Dergisi in Online Türk Sağlık Bilimleri Dergisi
- Vol. 6 (3) , 426-432
Open AccessSildenafil ve Bacillus Clausii’nin Metotreksat Bağlı Mukozitin Önlenmesindeki Rolü: Preklinik Çalışma
Objective: Methotrexate (MTX) is a commonly used chemotherapeutic agent in clinical oncology practice and in treatment of autoimmune diseases. The major side effect during treatment is mucositis. Recently published studies reported that this effect may be due to direct intestinal epithelial injury and disturbance of intestinal microbiota. In this study, we aimed to characterize the intestinal histological changes caused by MTX and to investigate the effects and safety of Sildenafil and probiotic Bacillus clausii on intestinal mucositis in a rat model. Materials and Methods: The rats were divided in 4 groups; Group1(n=8) received MTX + B. clausii, Group 2 (n=8) received only MTX, Group3 (n=8) received MTX + Sildenafil and Group 4 (n=7) was served as control (received no treatment). Results: The rate of villus atrophy, villous fusion and erosion in the MTX + B. clausii group were found to be statistically significantly lower than in the MTX group and the MTX + Sildenafil group. Conclusion: The study demonstrated the effect of B. clausii on repairing of intestinal mucosa after MTX-treatment. The better understanding of the effects of probiotics on intestinal mucosal protection may lead to new therapeutic approaches in chemotherapy-induced mucositis.